» Articles » PMID: 8548893

Platelet Function in Acute Myocardial Infarction Treated with Direct Angioplasty

Overview
Journal Circulation
Date 1996 Jan 15
PMID 8548893
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In acute myocardial infarction (AMI), platelets play a key role in thrombotic processes that limit the patency of the recanalized, infarct-related coronary artery and contribute to reperfusion injury. Platelet function in the course of AMI treated by direct percutaneous transluminal coronary angioplasty (PTCA) has not been evaluated.

Methods And Results: In 15 patients with anterior AMI, peripheral venous blood samples were obtained before and 4, 8, 24, and 48 hours after recanalization of the occluded artery by PTCA. Fifteen patients who had stable coronary heart disease and were undergoing elective balloon angioplasty served as control subjects. Fibrinogen receptor function and surface expression of P-selectin on platelets were determined by flow cytometry. In addition, we evaluated generation of platelet-derived microparticles and the effect of systemic plasma from patients with AMI on normal platelet function and on platelet adhesion to human endothelial cells in culture. We found fibrinogen receptor activity and P-selectin expression on circulating platelets 8 hours after direct PTCA are decreased (P < .01). This coincided with a decrease in peripheral platelet count (P < .05) and an increase in generation of microparticles (P < .002). Twenty-four to 48 hours after PTCA, fibrinogen receptor activity and P-selectin expression increased again. Systemic plasma obtained before and after direct PTCA sensitized normal platelets to hyperaggregate in vitro (P < .001) and stimulated platelet adhesion to endothelial cells in culture (P < .01). None of the changes found in AMI were detectable in the control group.

Conclusions: After transient apparent deactivation of circulating platelet, probably caused by sequestration of hyperactive platelets, the level of platelet activation increases in patients with AMI treated by direct PTCA. These findings underscore the need for novel antiplatelet strategies in AMI.

Citing Articles

Efficacy and safety of tirofiban in acute ischemic stroke patients with ideal reperfusion: A cohort study of LAA and CE subgroups.

Yue C, Liu X, Guo C, Wang L, Zhao W, Sun W Eur J Neurol. 2025; 32(1):e70034.

PMID: 39776227 PMC: 11707622. DOI: 10.1111/ene.70034.


Thromboinflammation is associated with clinical outcome after ST-elevation myocardial infarction.

Benkhoff M, Alde K, Ehreiser V, Dahlmanns J, Metzen D, Haurand J Blood Adv. 2024; 8(21):5581-5589.

PMID: 39226457 PMC: 11541696. DOI: 10.1182/bloodadvances.2024014273.


Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review.

Carciotto G, Costa F, Garcia-Ruiz V, Galli M, Soraci E, Magliarditi A J Clin Med. 2023; 12(22).

PMID: 38002756 PMC: 10672070. DOI: 10.3390/jcm12227144.


P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis.

Feng W, Chang Y, Lin Y, Chen H, Chen C, Lin T Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259380 PMC: 9958698. DOI: 10.3390/ph16020232.


Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction.

Polzin A, Dannenberg L, Benkhoff M, Barcik M, Helten C, Mourikis P Nat Commun. 2023; 14(1):2404.

PMID: 37100836 PMC: 10133218. DOI: 10.1038/s41467-023-38069-5.